The emergence of Nogo-A as one of the major MAIFs [15] and the identification of Nogo-66-induced growth cone collapse via NgR1, has led to the development of strategies aimed at overcoming Nogo-A-mediated neurite growth inhibition [16]-[20], thus providing some prospect for CNS regeneration and repair for neurodegenerative diseases with profound inflammation such as MS and spinal cord injury. Here, RTN4 is linked to myeloid sarcoma.